Zobrazeno 1 - 10
of 543
pro vyhledávání: '"zofenopril"'
Autor:
Sona Cacanyiova, Martina Cebova, Fedor Simko, Tomas Baka, Iveta Bernatova, Michal Kluknavsky, Stefan Zorad, Katarina Krskova, Ezgi Shaman, Anna Zemancikova, Andrej Barta, Basak G. Aydemir, Andrea Berenyiova
Publikováno v:
Biological Research, Vol 56, Iss 1, Pp 1-23 (2023)
Abstract Background Angiotensin converting enzyme 2 (ACE2) plays a crucial role in the infection cycle of SARS-CoV-2 responsible for formation of COVID-19 pandemic. In the cardiovascular system, the virus enters the cells by binding to the transmembr
Externí odkaz:
https://doaj.org/article/5aaaae2bd527423c9187dda7bfa601ac
Publikováno v:
Brazilian Journal of Pharmaceutical Sciences, Vol 58 (2022)
Abstract Angiotensin-II (AgII) is thought to be crucial for tumor growth and progression. Moreover, hydrogen sulfide (H2S) performs a controversial action in cancer pathology. Zofenopril (ZF) is an angiotensin-converting enzyme (ACE) inhibitor with H
Externí odkaz:
https://doaj.org/article/1955138f4f804ce6b702b0fc461d7af5
Publikováno v:
КардиоСоматика, Vol 10, Iss 4, Pp 23-28 (2019)
Aim. Еvaluate the influence of combination therapy with fosinopril or zofenopril on the regulatory-adaptive status (RAS) of patients with diastolic chronic heart failure (CHF). Material and methods. The study includes 80 patients with CHF I-II funct
Externí odkaz:
https://doaj.org/article/6a846bf1d9f249e5922e7a28bd1d02fa
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Tomas Jasenovec, Dominika Radosinska, Marta Kollarova, Peter Balis, Ezgi Dayar, Iveta Bernatova, Stefan Zorad, Norbert Vrbjar, Sona Cacanyova, Jana Radosinska
Publikováno v:
Biomedicines, Vol 9, Iss 12, p 1902 (2021)
Various pathologies (COVID-19 including) are associated with abnormalities in erythrocyte properties. Hypertension represents an unfavorable condition for erythrocyte quality and is the most prevalent risk factor in COVID-19 patients. ACE2 downregula
Externí odkaz:
https://doaj.org/article/a11f2b991e024ba18ed5310c7a757086
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Фармакоэкономика, Vol 9, Iss 4, Pp 3-8 (2017)
Objective. Pharmacoeconomic analysis of the use of combinations of antihypertensive drugs were olmesartan/lercanidipine and zofenopril/lercanidipine in patients with essential hypertension II-III stage.Materials and methods. The authors performed pro
Externí odkaz:
https://doaj.org/article/1ff1f6ae280641448ec7c1d8cf6ec95b
Autor:
O. V. Zimnitskaya, M. M. Petrova
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 12, Iss 5, Pp 536-541 (2016)
Aim. To study the effect of olmesartan/lercanidipine combination and zofenopril/lercanidipine combination on the level of soluble platelet-endothelial cell adhesion molecule of the first type (sPECAM-1) in plasma in patients with essential hypertensi
Externí odkaz:
https://doaj.org/article/fbce4d27124f4dc98e4cf23b82792515
Publikováno v:
Archives of Medical Science : AMS
IntroductionObstruction of the ureter may occur due to congenital, iatrogenic or other reasons. This can cause hydronephrosis in the early stage and can lead to cellular inflammation, necrosis and atrophy in the kidney tissue. The aim of this paper i
Publikováno v:
КардиоСоматика, Vol 7, Iss 2, Pp 42-46 (2016)
Objective. Optimization of drug therapy in patients with stable coronary heart disease and arterial hypertension (AH) in the application of ACE inhibitors: zofenopril compared with enalapril. Material and methods. We studied 80 patients with stable a
Externí odkaz:
https://doaj.org/article/1cd57b04999844a68d9045e9c2a9aa4d